MX2018009904A - Escision de secuencias de acido nucleico retrovirales. - Google Patents
Escision de secuencias de acido nucleico retrovirales.Info
- Publication number
- MX2018009904A MX2018009904A MX2018009904A MX2018009904A MX2018009904A MX 2018009904 A MX2018009904 A MX 2018009904A MX 2018009904 A MX2018009904 A MX 2018009904A MX 2018009904 A MX2018009904 A MX 2018009904A MX 2018009904 A MX2018009904 A MX 2018009904A
- Authority
- MX
- Mexico
- Prior art keywords
- excision
- nucleic acid
- acid sequences
- retroviral nucleic
- compositions
- Prior art date
Links
- 230000001177 retroviral effect Effects 0.000 title abstract 2
- 150000007523 nucleic acids Chemical group 0.000 title 1
- 108091033409 CRISPR Proteins 0.000 abstract 2
- 208000031873 Animal Disease Models Diseases 0.000 abstract 1
- 238000010354 CRISPR gene editing Methods 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000011558 animal model by disease Methods 0.000 abstract 1
- 238000010362 genome editing Methods 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295390P | 2016-02-15 | 2016-02-15 | |
| US201662298722P | 2016-02-23 | 2016-02-23 | |
| US201662337994P | 2016-05-18 | 2016-05-18 | |
| US201662345520P | 2016-06-03 | 2016-06-03 | |
| US201662363625P | 2016-07-18 | 2016-07-18 | |
| US201662410496P | 2016-10-20 | 2016-10-20 | |
| PCT/US2017/017652 WO2017142835A1 (en) | 2016-02-15 | 2017-02-13 | Excision of retroviral nucleic acid sequences |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018009904A true MX2018009904A (es) | 2019-07-08 |
Family
ID=59626223
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009904A MX2018009904A (es) | 2016-02-15 | 2017-02-13 | Escision de secuencias de acido nucleico retrovirales. |
| MX2023005397A MX2023005397A (es) | 2016-02-15 | 2018-08-15 | Escision de secuencias de acido nucleico retrovirales. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005397A MX2023005397A (es) | 2016-02-15 | 2018-08-15 | Escision de secuencias de acido nucleico retrovirales. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12122997B2 (enExample) |
| EP (1) | EP3417062B1 (enExample) |
| JP (1) | JP7176737B2 (enExample) |
| CN (1) | CN109415728A (enExample) |
| AU (1) | AU2017219605B2 (enExample) |
| CA (1) | CA3014631A1 (enExample) |
| MX (2) | MX2018009904A (enExample) |
| WO (1) | WO2017142835A1 (enExample) |
| ZA (2) | ZA201806060B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| AU2014312123A1 (en) | 2013-08-29 | 2016-03-17 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| KR102553518B1 (ko) | 2015-06-01 | 2023-07-07 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Hiv 감염의 rna-가이드된 치료를 위한 방법 및 조성물 |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| EP3417062B1 (en) | 2016-02-15 | 2024-06-26 | Temple University - Of The Commonwealth System of Higher Education | Excision of retroviral nucleic acid sequences |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| DE112020001306T5 (de) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| AU2021230546A1 (en) | 2020-03-04 | 2022-10-13 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| CN113528514B (zh) * | 2020-04-22 | 2023-05-05 | 中国科学院分子植物科学卓越创新中心 | 基于CRISPR-Cas12a干预阻断病毒逆转录转座的技术 |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| JP2023544382A (ja) * | 2020-10-02 | 2023-10-23 | テンプル ユニヴァーシティ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｒｎａによる単純ヘルペスｉ型およびその他の関連するヒトヘルペスウイルスの根絶 |
| WO2022256294A1 (en) * | 2021-06-01 | 2022-12-08 | University Of Massachusetts | Cas9 nickase-mediated gene editing |
| US20240342106A1 (en) * | 2021-07-27 | 2024-10-17 | University Of Miami | Nanoparticles and uses thereof for treatment of human immunodeficiency virus |
| CA3231677A1 (en) | 2021-09-08 | 2023-03-16 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP2485759A4 (en) | 2009-10-09 | 2013-07-24 | Univ New York | METHOD, AGENTS AND PEPTIDES FOR GENERATING A BORN IMMUNE RESPONSE IN HIV VACCINATION |
| KR20150105956A (ko) * | 2012-12-12 | 2015-09-18 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화 |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| AU2014312123A1 (en) * | 2013-08-29 | 2016-03-17 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| CN104726449A (zh) * | 2015-03-23 | 2015-06-24 | 国家纳米科学中心 | 一种用于预防和/或治疗HIV的CRISPR-Cas9系统及其制备方法和用途 |
| EP3417062B1 (en) | 2016-02-15 | 2024-06-26 | Temple University - Of The Commonwealth System of Higher Education | Excision of retroviral nucleic acid sequences |
-
2017
- 2017-02-13 EP EP17753686.9A patent/EP3417062B1/en active Active
- 2017-02-13 CN CN201780023772.9A patent/CN109415728A/zh active Pending
- 2017-02-13 MX MX2018009904A patent/MX2018009904A/es unknown
- 2017-02-13 WO PCT/US2017/017652 patent/WO2017142835A1/en not_active Ceased
- 2017-02-13 CA CA3014631A patent/CA3014631A1/en active Pending
- 2017-02-13 JP JP2018543090A patent/JP7176737B2/ja active Active
- 2017-02-13 US US15/998,558 patent/US12122997B2/en active Active
- 2017-02-13 AU AU2017219605A patent/AU2017219605B2/en active Active
-
2018
- 2018-08-15 MX MX2023005397A patent/MX2023005397A/es unknown
- 2018-09-10 ZA ZA2018/06060A patent/ZA201806060B/en unknown
-
2020
- 2020-07-10 US US16/926,427 patent/US20200392487A1/en not_active Abandoned
-
2022
- 2022-06-01 ZA ZA2022/06102A patent/ZA202206102B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3417062A1 (en) | 2018-12-26 |
| JP2019504868A (ja) | 2019-02-21 |
| CN109415728A (zh) | 2019-03-01 |
| AU2017219605A1 (en) | 2018-09-20 |
| ZA201806060B (en) | 2023-01-25 |
| EP3417062A4 (en) | 2019-12-11 |
| WO2017142835A1 (en) | 2017-08-24 |
| EP3417062B1 (en) | 2024-06-26 |
| US20200392487A1 (en) | 2020-12-17 |
| US20190225963A1 (en) | 2019-07-25 |
| ZA202206102B (en) | 2023-09-27 |
| MX2023005397A (es) | 2023-05-19 |
| AU2017219605B2 (en) | 2023-04-13 |
| JP7176737B2 (ja) | 2022-11-22 |
| US12122997B2 (en) | 2024-10-22 |
| CA3014631A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202206102B (en) | Excision of retroviral nucleic acid sequences | |
| JOP20210231A1 (ar) | مركبات ترابطية مستهدفة كمركبات علاجية | |
| JOP20210207A1 (ar) | مركبات ترابطية مستهدفة | |
| EP4406585A3 (en) | Nucleic acid products and methods of administration thereof | |
| MX2018001617A (es) | Composiciones de crispr-cas9 diseñados y metodos de uso. | |
| HUS2500003I1 (hu) | Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| WO2016049024A3 (en) | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo | |
| EP4249036A3 (en) | Methods and products for nucleic acid production and delivery | |
| CN105593367A8 (zh) | CRISPR‑Cas9特异性敲除猪SLA‑1基因的方法及用于特异性靶向SLA‑1基因的sgRNA | |
| EA201700181A1 (ru) | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования | |
| MX388127B (es) | Metodos y composiciones para la modificacion dirigida de un genoma. | |
| HUE055002T2 (hu) | Nukleinsav-konstrukciók és génterápiás vektorok Wilson-kór kezelésében történõ alkalmazásra | |
| WO2017059223A3 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| SG10201805815YA (en) | Rna-guided gene drives | |
| MX2017000143A (es) | Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos. | |
| WO2013170170A3 (en) | Compositions and methods for gene therapy | |
| IL280962A (en) | Methods for delivering gene editing reagents to cells within organs | |
| EA201692318A1 (ru) | Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина | |
| EP4410976A3 (en) | Methods of using zscan4 for rejuvenating human cells | |
| PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| CY1120084T1 (el) | Oλiγονουκλεοτiδiα για τη ρυθμιση της γονιδιακης εκφρασης και οι χρησεις αυτων | |
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| WO2016048861A3 (en) | Heterocyclic compounds and use thereof | |
| MY168778A (en) | Oligonucleotide chelate complex-polypeptide compositions and methods |